Related Experiment Videos

Hepatic function in relation to acetylator phenotype in children treated with antitubercular drugs

Insights

Investigating hepatotoxicity in children with pulmonary primary complex revealed no significant differences based on acetylator phenotype. Lower drug dosages of isoniazid and rifampin effectively reduced liver damage, regardless of acetylator type.

Area of Science:

  • Pediatric Pulmonology
  • Hepatology
  • Clinical Pharmacology

Background:

  • Pulmonary primary complex is a significant health concern in children.
  • Hepatotoxicity is a known side effect of antitubercular drugs.
  • The role of acetylator phenotype in drug-induced liver injury requires further investigation.

Purpose of the Study:

  • To investigate hepatotoxicity in children with pulmonary primary complex.
  • To determine the relationship between acetylator phenotype and drug-induced liver injury.
  • To assess the impact of malnutrition on drug-induced liver injury.

Main Methods:

  • Sixty-six children with pulmonary primary complex were studied.
  • Acetylator phenotype was determined using the sulphadimidine acetylation test.
  • Liver function tests (SGOT, SGPT) were monitored over one year.

Main Results:

  • No biochemical evidence of hepatic derangement was found in relation to acetylator phenotype.
  • Hepatotoxicity was significantly reduced with lower dosages of isoniazid and rifampin.
  • Mild malnutrition did not increase the risk of hepatotoxicity.

Conclusions:

  • Acetylator phenotype does not appear to influence hepatotoxicity in children with pulmonary primary complex.
  • Lower drug dosages are crucial for mitigating liver damage from antitubercular therapy.
  • Mild malnutrition does not exacerbate drug-induced liver injury in this population.

Related Concept Videos